Showing 4381-4390 of 5771 results for "".
- Influx of New Contact Lens Patients Calls for Simplified Wear-and-Care Educationhttps://modernod.com/news/influx-of-new-contact-lens-patients-calls-for-simplified-wear-and-care-education/2478671/Within days of mask guidelines being implemented earlier this year, the reports of fogging started streaming in from glasses and sunglasses wearers. Social feeds were soon packed with photos of the annoying condensation and news reports began offering tips on how to avoid condensation. In 2020, t
- Glaucoma Research Foundation Encourages Patients to Visit Their Eye Doctor for the Care They Need During COVID-19 Pandemichttps://modernod.com/news/glaucoma-research-foundation-encourages-patients-to-visit-their-eye-doctor-for-the-care-they-need-during-covid-19-pandemic/2478670/Glaucoma Research Foundation (GRF) announced the release of a 6-minute video designed to encourage glaucoma patients to visit their eye care provider for the care they need during the COVID-19 pandemic. The free video
- Optos Introduces Ultra-Widefield Imaging Advancementshttps://modernod.com/news/optos-introduces-ultra-widefield-imaging-advancements/2478659/Optos has announced the introduction of several advancements to its Ultra-Widefield (UWF) imaging devices. The Optos platform, which includes Daytona, California, Monaco, and Silverstone, is the only retinal imaging t
- Nicox Initiates Phase 2b Trial of NCX 4251, a Potential First-in-Class Treatment for Blepharitishttps://modernod.com/news/nicox-initiates-phase-2b-trial-of-ncx-4251-a-potential-first-in-class-treatment-for-blepharitis/2478662/Nicox SA announced the initiation of the Mississippi trial, a phase 2b clinical trial of NCX 4251, evaluating once-daily dosed NCX 4251 0.1% versus placebo in patients with acute exacerbations of blepharitis. NCX 4251 is a novel patented ophthalmic suspension of fluticasone propionate nanocrystal
- Novartis Reports Positive Topline Results From Second Phase 3 Trial of Beovu in Patients With DMEhttps://modernod.com/news/novartis-reports-positive-topline-results-from-second-phase-3-trial-of-beovu-in-patients-with-dme/2478658/Novartis announced positive findings from the first interpretable results of the phase 3 KESTREL study, assessing the efficacy and safety of Beovu (brolucizumab) 3 mg and 6 mg in diabetic macular edema (DME). Following KITE, KESTREL is the second pivotal phase 3 study of Beovu in DME. The
- CureVac Commences Global Pivotal Phase 2b/3 Trial for COVID-19 Vaccine Candidate, CVnCoVhttps://modernod.com/news/curevac-commences-global-pivotal-phase-2b-3-trial-for-covid-19-vaccine-candidate-cvncov/2478656/CureVac announced that it has enrolled the first participant in the pivotal phase 2b/3 study of its mRNA vaccine candidate, CVnCoV, against COVID-19. The randomized, observer blind, placebo-controlled phase 2b/3 trial
- US Government to Buy 100 Million More Doses of Moderna’s COVID-19 Vaccinehttps://modernod.com/news/us-government-to-buy-100-million-more-doses-of-modernas-covid-19-vaccine/2478657/Moderna announced that the US government has exercised its option to purchase an additional 100 million doses of the drugmaker’s COVID-19 vaccine candidate mRNA-1273, bringing its confirmed order commitment to 200 million doses in the US. CEO Stéphane Bancel remarked that “we c
- Nicox’s Partner Fera Pharmaceuticals to Investigate Naproxcinod as Potential COVID-19 Adjuvant Treatmenthttps://modernod.com/news/nicoxs-partner-fera-pharmaceuticals-to-investigate-naproxcinod-as-potential-covid-19-adjuvant-treatment/2478649/Nicox and Fera Pharmaceuticals announced that Fera will evaluate naproxcinod as a potential adjuvant treatment for patients with COVID-19 infection. Subject to successful completion of the ongoing manufacturing of naproxcinod test material, Fera plans to init
- EyeQue to Launch VisionCheck 2 Do-It-Yourself Smartphone Vision Testhttps://modernod.com/news/eyeque-to-launch-visioncheck-2-do-it-yourself-smartphone-vision-test/2478648/EyeQue announced the upcoming launch of EyeQue VisionCheck 2, a refraction device available for consumers to test their own vision and order new glasses from home. VisionCheck 2 is a lightweight optical smartphone attachment and mobile app. The test results are expr
- Foundation Fighting Blindness Appoints Peter Ginsberg as Executive Vice President, Corporate Development, Chief Business Officerhttps://modernod.com/news/foundation-fighting-blindness-appoints-peter-ginsberg-as-executive-vice-president-corporate-development-chief-business-officer/2478647/The Foundation Fighting Blindness announced the appointment of Peter Ginsberg as executive vice president, corporate development, chief business officer. Mr. Ginsberg will oversee the development of financial plans and processes while providing leadership on busines